Replies to post #3634 on $Bob's and Jbem's Bitchin' Bios

[bUrRpPPP!]

MEIP Updated ASH data....Thoughts?

CONCLUSIONS
• Pracinostat in combination with azacitidine demonstrates significant clinical activity in elderly
patients with newly diagnosed AML
§§ To date, 15 of 33 patients (45%) achieved the primary endpoint of CR + CRi + MLFS
§§ No patient who achieved a clinical response has progressed
§§ Most clinical responses occur within the first 2 cycles and continue to improve with
ongoing therapy
§§ The observed response rate may increase with longer follow-up of patients achieving PR or
SD (stable disease)
• Pracinostat in combination with azacitidine was well tolerated in this population of elderly AML
patients
§§ The most common treatment-emergent AEs included neutropenia, febrile neutropenia,
thrombocytopenia, nausea, fatigue, and anemia
§§ Adverse events resulting in dose reductions were uncommon, and frequently due to
disease under study
§§ The 60-day mortality rate is approximately 10% (3/33)
§§ 6 patients to date have received study drug beyond 230 days, reflecting long-term
tolerability
• These data support definitive development of pracinostat in combination with azacitidine in
elderly AML patients